Table 1 Patient characteristics and estimated probability of adherence
Characteristics | Adherent/total | Adherent % (95% CI) | Non-adherent/total | Non-adherent % (95% CI) |
|---|---|---|---|---|
903/1192 | 75.8 (73.2-78.1) | 289/1192 | 24.2 (21.8-26.8) | |
Age at diagnosis | ||||
< 40 | 36/59 | 61.0 (47.4-73.5) | 23/59 | 39.0 (26.5-52.6) |
40-49 | 164/195 | 84.1 (78.2-88.9) | 31/195 | 15.9 (11.1-21.8) |
50-59 | 282/350 | 80.6 (76.0-84.6) | 68/350 | 19.4 (15.4-24.0) |
60-69 | 269/350 | 76.9 (72.1-81.2) | 81/350 | 23.1 (18.8-27.9) |
70-79 | 104/138 | 75.4 (67.3-82.3) | 34/138 | 24.6 (17.7-32.7) |
≥ 80 | 48/100 | 48.0 (37.9-58.2) | 52/100 | 52.0 (42.8-63.1) |
Tumour stage | ||||
T1 | 508/686 | 74.1 (70.6-77.3) | 178/686 | 25.9 (22.8-29.6) |
T2 | 275/356 | 77.2 (72.5-81.5) | 81/356 | 22.8 (18.5-27.5) |
T3-T4 | 28/32 | 87.5 (71.0-96.5) | 4/32 | 12.5 (3.5-29.0) |
Unknowna | 92/118 | 78.0 (69.4-85.1) | 26/118 | 22.0 (14.9-30.6) |
Histopathological type | ||||
Ductal | 712/943 | 75.5 (72.5-78.1) | 231/943 | 24.5 (21.8-27.3) |
Lobular | 122/153 | 79.7 (72.5-85.8) | 31/153 | 20.3 (14.2-27.5) |
Other | 64/89 | 71.9 (61.4-80.9) | 25/89 | 28.1 (19.1-38.6) |
Unknown | 5/7 | 71.4 (29.0-96.3) | 2/7 | 28.6 (3.7-71.0) |
Histological grade | ||||
Grade 1 | 76/104 | 73.1 (63.5-81.3) | 28/104 | 26.9 (18.7-36.5) |
Grade 2 | 507/686 | 73.9 (70.4-77.0) | 179/686 | 26.1 (23.0-29.7) |
Grade 3 | 229/285 | 80.4 (75.3-84.8) | 56/285 | 19.6 (15.2-24.7) |
Unknown | 91/117 | 77.8 (69.2-84.9) | 26/117 | 22.2 (15.1-30.8) |
Axillary lymph node metastasis | ||||
0 | 473/665 | 71.1 (67.4-74.4) | 192/665 | 28.9 (25.6-32.6) |
1-3 | 280/334 | 83.8 (79.4-87.6) | 54/334 | 16.2 (12.4-20.6) |
≥ 4 | 119/143 | 83.2 (76.1-88.9) | 24/143 | 16.8 (11.1-23.9) |
Unknown | 31/50 | 62.0 (47.2-75.3) | 19/50 | 38.0 (24.7-52.8) |
Neoadjuvant treatment | ||||
No | 764/1017 | 75.1 (72.3-77.7) | 253/1017 | 24.9 (22.2-27.7) |
Yes | 139/175 | 79.4 (72.7-85.2) | 36/175 | 20.6 (14.8-27.3) |
Type of antihormonal treatment | ||||
Tamoxifen only | 169/231 | 73.2 (67.0-78.8) | 62/231 | 26.8 (21.2-33.0) |
Tamoxifen ➔ AI | 298/343 | 86.9 (82.8-.90.3) | 45/343 | 13.1 (9.7-17.2) |
AI only | 284/336 | 84.5 (80.2-88.2) | 52/336 | 15.5 (11.8-19.8) |
AI ➔ Tamoxifen | 93/111 | 83.8 (75.6-90.1) | 18/111 | 16.2 (9.9-24.4) |
More than one switch | 59/70 | 84.3 (73.6-91.9) | 11/70 | 15.7 (8.1-26.4) |
No antihormonal treatment registered | 0/101 | 0 (0- 3.6) | 101/101 | 100 (96.4-100) |
Switch at two years | ||||
Nob | 208/253 | 82.2 (76.9-86.7) | 45/253 | 17.8 (13.3-23.1) |
Yes | 245/276 | 88.8 (84.4-92.2) | 31/276 | 11.2 (7.8-15.5) |
Monotherapy | 450/562 | 80.1 (76.5-83.3) | 112/562 | 19.9 (16.7-23.5) |
No antihormonal treatment registered | 0/101 | 0 (0- 3.6) | 101/101 | 100 (96.4-100) |
Radiation therapy | ||||
No | 234/345 | 67.8 (62.6-72.7) | 111/345 | 32.2 (27.2-37.4) |
Yes | 669/847 | 79.0 (76.1-81.7) | 178/847 | 21.0 (18.3-23.9) |
Chemotherapy | ||||
No | 379/576 | 65.8 (61.8-69.7) | 197/576 | 34.2 (30.5-38.4) |
Yes | 524/616 | 85.1 (82.0-87.8) | 92/616 | 14.9 (12.2-18.0) |